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Abstract
CRISPR is widely used to disrupt gene function by inducing small insertions and deletions. Here, we show that some
single-guide RNAs (sgRNAs) can induce exon skipping or large genomic deletions that delete exons. For example,
CRISPR-mediated editing of β-catenin exon 3, which encodes an autoinhibitory domain, induces partial skipping of the
in-frame exon and nuclear accumulation of β-catenin. A single sgRNA can induce small insertions or deletions that
partially alter splicing or unexpected larger deletions that remove exons. Exon skipping adds to the unexpected
outcomes that must be accounted for, and perhaps taken advantage of, in CRISPR experiments.
Background
CRISPR/Cas9 genome editing has transformed the study
of gene function in many organisms [1–5]. Guide RNAs
direct the Cas9 nuclease to create double-strand DNA
breaks at complementary target sites in the genome.
Repair of these double-strand DNA breaks by non-
homologous end-joining (NHEJ) often introduces small
insertions or deletions (indels) that shift the open read-
ing frame, thereby inactivating the target gene. CRISPR
therefore provides a simple way to generate loss-of-
function (LOF) mutations in virtually any gene in the
mammalian genome [1]. Nonetheless, CRISPR can also
induce off-target editing at genomic positions that
imperfectly match the single-guide RNA (sgRNA) se-
quence, which calls for the implementation of strategies
to reduce off-target effects [6, 7]. Besides off-target
editing, it remains unknown whether CRISPR-mediated
editing has unintended consequence at the post-
transcriptional level of the target gene.
We have previously used in vivo delivery of CRISPR to
inactivate tumor suppressor genes in mice [8–10]. We
also showed that CRISPR can edit oncogenes or disease
genes through homolog-directed repair [8, 11, 12]. Here
we show that CRISPR-mediated editing of mammalian
exons can induce exon skipping. Exon skipping can
result from alternative splicing or from genomic dele-
tions that remove exons. Moreover, exon skipping can
produce messenger RNAs (mRNAs) with intact reading
frames that encode functional proteins.
Results
We recently used CRISPR to disrupt the Kras oncogene
in two independent lung adenocarcinoma cell lines [13],
which were derived from KrasG12D; p53fl/fl (KP) mice
[14, 15]. We isolated two single-cell clones each carrying
frameshifting deletions in exon 2 (Fig. 1a and Additional
file 1: Figure S1a): KP1 carries a 2-nt “-CG” deletion in the
G12D allele and a 1-nt “-C” deletion in the otherwise
wild-type (WT) Kras allele; and KP2 carries a 2-nt “-GG”
deletion. Neither clone produces full length Kras protein
[13], indicating that all three deletions disrupt the Kras
reading frame.
Frameshift mutations in early exons are known to
trigger nonsense-mediated decay (NMD) [16], which
eliminates mRNAs with premature termination codons.
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When we analyzed mRNA-sequencing (RNA-seq) data,
however, we found that apparent Kras mRNA levels
(i.e. total normalized mRNA reads) were only reduced
by 19% in KP1 cells and 47% in KP2 cells, compared
with parental KP cells (Fig. 1b). Both clones produced
fewer exon 2 reads, but normal levels of exon 1 and 3
reads (Fig. 1c), suggesting that exon 2 might be skipped
in the KP1 and KP2 clones. Indeed, we detected exon
1-3 junction reads, indicating that exon 2 was skipped
(Fig. 1c and Additional file 1: Figure S1b). Calculating
the ratio between exon 2 reads and total reads, we
found that exon 2 is included in only 64.0 ± 9.1% of
Kras reads from KP1-clone (Fig. 1c and Table 1).
Similar exon 2 skipping was observed in KP2-clones
(Additional file 1: Figure S1c). Concordantly, reverse
transcription of Kras mRNA followed by polymerase
chain reaction (RT-PCR) yielded two products: one cor-
responded to intact Kras complementary DNA (cDNA)
and the other corresponded to the exon 1-3 isoform
(Fig. 1d). The exon 1-3 isoform retains a partial Kras
open reading frame that could initiate translation from
an ATG codon in exon 3 (Additional file 1: Figure S2)
and produce a severely truncated Kras protein.
Editing of Kras did not induce alternative splicing
genome-wide. We identified 97 alternatively spliced
exons in KP1 cells and 177 events in KP2 cells. KP1 and
KP2 clones shared 22 cassette inclusion or exclusion
events, with the exclusion of Kras exon 2 being the
greatest change in both clones (Fig. 1e and Additional
file 1: Table S3). Thus, editing of Kras exon 2 specifically
induced skipping of Kras exon 2. Notably, whereas
mouse KrasG12D (GGU to GAU) transcripts do not skip
Fig. 1 sgRNA targeting Kras induces exon skipping in single cell clones. a Schematic of an sgRNA targeting exon 2 of the mouse Kras gene (sgKras).
The red arrowhead denotes the Cas9 cleavage site. KP1 and KP2 cell lines were transduced with lentivirus that encodes Cas9 and sgKras.
Two single-cell clones (KP1 clone and KP2 clone) harbor frameshift deletions. Black arrows indicate the positions of reverse transcription polymerase
chain reaction (RT-PCR) primers. The G12D codon is underlined. b Normalized Kras read counts from RNA-sequencing (RNA-seq) analysis of KP parental
cells (blue) and KP clones (red). RNA-seq was done twice for KP2 clone and three times for the other groups. “+” denotes WT allele. c RNA-seq showing
partial exon 2 skipping in KP1 clones. RNA-seq numbers indicate reads spanning the indicated exon junctions. Two representative biological replicates
are shown. d RT-PCR analysis of Kras mRNA detects an exon 2 skipped band. The expected band sizes are 331 bp and 209 bp. M, molecular
marker. “*” denotes indels in PCR products from clones. e Scatter plot showing 22 exon events that change in both KP1 and KP2 clones. Exclusion of
Kras exon 2 is the most frequent event. Ψ, Percentage Splicing Index
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exon 2 in parental KP cells, we found that ~15% of
human KRASG12S (codon 12 GGU to AGU) transcripts
skip exon 2 in the A549 human lung cancer cell line
(Additional file 1: Figure S1d). We were unable to pre-
dict the gain or loss of exon splice enhancers or silencers
[17], but our data suggest that sequences near Kras
codon 12 promote exon 2 inclusion in mouse and
human Kras. Exon skipping induced by CRISPR editing
was not limited to Kras or to mouse KP cells. A recent
study showed that CRISPR editing of FLOT1 exon 3 in
HeLa cells can cause skipping of exon 3, exon 4, or
exons 3, 4, and 5 [18]. We also detected infrequent exon
skipping when we targeted exon 11 of LMNA in human
HCT116 cells (Additional file 1: Figure S3). Skipping
LMNA exon 11 produces an in-frame transcript that
could be translated into a neomorphic protein.
To further explore the idea that exon skipping could
produce a functional in-frame transcript, we asked
whether CRISPR-mediated editing of Ctnnb1 exon 3
might induce exon skipping and cause a gain-of-function
phenotype. Exon 3 of Ctnnb1 encodes phosphoacceptor
residues that promote degradation of the β-Catenin tran-
scription factor [19]; genetic excision of Ctnnb1 exon
3—which is in frame with exon 4—stabilizes a constitu-
tively active β-Catenin that accumulates in the nucleus
[20, 21]. We designed 11 sgRNAs that target regions along
Ctnnb1 exon 3 (Ctnnb1-sg1 to -sg11), transduced individ-
ual sgRNAs into KP cells, and used high-throughput
sequencing to analyze the extent of editing at the sgRNA
target site in each line (Fig. 2b x-axis, Additional file 1:
Figure S4 and Additional file 2: Table S4). Three sgRNAs
(sg6, sg9, and sg10) inefficiently targeted Ctnnb1. Eight of
the Ctnnb1 sgRNAs (sg1 to sg5, sg7, sg8, and sg11),
however, induced indels at their target sites with frequen-
cies that exceeded 20%. For example, Ctnnb1-sg1 gener-
ated + T insertions in about 65% of reads (Fig. 2c). In each
population targeted by a strong Ctnnb1 sgRNA, we
detected three RT-PCR products that span exons 2 to 5
(Fig. 2d). The major product corresponds to the normally
spliced transcript that includes exon 3. The other two
products correspond to alternatively spliced transcripts:
one that skips exon 3 (i.e. exon 2-4 splicing, Fig. 2e) and
one that skips both exons 3 and 4 (i.e., exon 2-5 splicing,
Fig. 2f). Ctnnb1 sgRNAs targeting either DNA strand in-
duced exon skipping and Cas9 nuclease activity was es-
sential for exon skipping (Fig. 3a).
Western blot analysis revealed that cell populations
transduced with the strong sgRNAs produce a smaller
~74 kD β-Catenin protein that corresponds in size to
that expected from the exon 2-4 splice product (Fig. 2g).
The full length β-Catenin protein was not significantly
depleted four days after transduction. To test whether
the alternative splicing is dependent on the continuous
expression of Cas9 or sgRNA in the lentiviral vectors,
we co-transfected Cas9 and Ctnnb1-sg1 or a non-
targeting sgRNA control. Seven days after transfection,
when transfected Cas9 and guide RNAs should be de-
pleted, we examined β-Catenin localization by immuno-
fluorescence. In mouse fibroblast cells transfected with a
non-targeting control sgRNA, β-Catenin localized to cell
junctions (Additional file 1: Figure S5a). By contrast, in
many cells transfected with Ctnnb1-sg1, we detected
β-Catenin in the nucleus (Additional file 1: Figure S5a).
These results suggest that continuous editing is not
required for exon skipping and that exon 3 skipping
induced by CRISPR-mediated editing of Ctnnb1 exon 3
produces a gain-of-function β-Catenin isoform.
We further analyzed transcripts spanning exons 2 to 7
in cell populations treated with Ctnnb1-sg2, -sg3, and
-sg5. In addition to the full-length isoform, we detected
four transcripts with exon 2 apparently spliced to each
downstream exon (i.e. exon 2-4, exon 2-5, exon 2-6, and
exon 2-7; Fig. 3a, b). We do not understand the mechan-
ism of this apparently promiscuous exon skipping
Table 1 Genomic lesion and mRNA splicing results of single cell clones
Gene/clone sgRNA target Allele Genomic lesion Exon inclusion (%)
Kras (KP1) Exon 2 1 -CG 64.0 ± 9.1b
2 -C
Krasa (KP2) Exon 2 1 -GG 68.0 ± 7.1b
Ctnnb1c Exon 3 1 -CCA 100
2 832 bp deletion New mRNA isform with part
of intron 2 and exon 4
p65 clone 15 Exon 6 1 +A 100
2 2.2 kb deletion (exons 5, 6, 7) ND
p65 clone 31a Exon 6 1 +A 100
aClones with one allele
b% exon inclusion is mean ± s.d. (n = 3 for KP1 and n = 2 for KP2)
cClone in Additional file 1: Figure S6
ND not determined
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induced by Ctnnb1 exon 3 editing, nor have we been
able to correlate promiscuous exon skipping with spe-
cific target sites or indel mutations in exon 3. Neverthe-
less, we isolated a Ctnnb1-sg3 edited clone that suggests
a potential mechanism (Additional file 1: Figure S6a).
This biallelic clone contains a 3-bp in-frame deletion on
one allele and a large 832-bp deletion on the other; the
832-bp deletion fuses the 5’ end of intron 2 to the 3’ end
of exon 4 (Additional file 1: Figure S6). We detected two
transcripts in these cells: the properly spliced transcript
that includes the 3-bp deletion and a transcript that
includes intron 2 fused to exon 4 (Additional file 1:
Figure S6c and Table 1). These results suggest that
apparent exon skipping detected in populations of
edited cells could reflect genome rearrangements that
remove exons.
Two experiments support the idea that a single sgRNA
can induce large genomic deletions that remove exons.
For example, we isolated 15 clones from mouse 3T3
cells transiently transfected with Cas9 and Ctnnb1-sg1,
and found that four clones (i.e. clones 4, 5, 13, and 15)
showed apparent exon skipping by RT-PCR. Genomic
PCR revealed genome rearrangements in three of these
clones: large deletions (>500 bp) and smaller deletions
(~100 bp) in clones 4 and 15, and large insertions in
clones 13 and 15 (Additional file 1: Figure S7). More-
over, after targeting exon 6 of p65/RelA, we isolated a
biallelic p65 clone (#15): one allele harbors a 1-nt “+A”
insertion and the other harbors a 2268-bp deletion
that removes exons 5, 6, and 7 (Additional file 1:
Figure S8a, c–e). In p65 clone #15, we detected the
fully spliced transcript and an exon 4-8 splice product
Fig. 2 Ctnnb1 sgRNAs targeting exon 3 induces exon skipping. a Schematic of the Ctnnb1 gene. The in-frame exon 3 encodes an inhibitory domain:
phosphorylation amino acids 33, 37, 41, and 45 promotes degradation of the β-Catenin protein. Loss of exon 3 stabilizes β-Catenin. Eleven sgRNAs
were designed to target exon 3: strong sgRNAs in red and weak sgRNAs in black, respectively. sgRNAs that use “NGG” PAM are shown above exon 3
and those that use “CCN” PAM are shown below exon 3. b Correlation between exon 3 skipping and sgRNA efficiency. Genomic indels were measured
by deep sequencing. KP cells were infected with lentivirus. Exon 3 skipping efficiencies are from (d). Indels of sg11 were not determined. sgRNAs that
induce > 20% indels are marked in red. c Distribution of sg1 indels shows that a T insertion (+T) at the Cas9 cleavage site nucleotide 97
of exon 3 (red arrowhead) was the most frequent. PAM sequence is in blue. d RT-PCR using primers spanning exons 2 and 5 shows partial exon skipping.
M molecular marker. sgGFP is a control sgRNA. Exon 3 skipping bands were quantified using ImageQuant TL software and normalized to full length
cDNA bands. sg4 showed visible weak bands that could not be quantified. e, f TOPO cloning and Sanger sequencing confirmed that the two major
lower RT-PCR bands in (c) are alternative splicing of exon 2-4 and exon 2-5, respectively. g Western blot analysis of β-Catenin. Full length β-Catenin is
~86 kD. β-Catenin without exon 3 (delta exon 3) is ~77 kDa. Actin served as a loading control
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(Additional file 1: Figure S8c). Both alleles encode frame-
shifted transcripts and both p65 transcripts are present at
lower levels than WT (Additional file 1: Figure S8b). We
also isolated an edited p65 clone (#31) homozygous for the
same +A insertion as in clone #15, but clone #31 does not
produce alternatively spliced transcripts. Thus, the exon 4-8
spliced transcript in clone #15 results from the deletion of
exons 5, 6, and 7. These large exon deletion events were
unexpected and would be missed using typical PCR-based
screening assays.
The ability to cause a gain-of-function activity by indu-
cing exon skipping or exon excision suggested that
CRISPR-meditated editing using a single sgRNA might
be a useful way to partially rescue function to a disease
gene that requires low-level rescue. CRISPR-mediated
homologous DNA repair has been used to correct
premature stop codon mutations in the Dmd gene in a
mouse model of DMD [22] and several groups have used
CRISPR to delete Dmd exons and partially restore Dmd
expression [23–26]. We designed four sgRNA/Cas9 len-
tiviruses that target different sites in exon 23 of the Dmd
gene (Fig. 4a, b) and transduced mouse C2C12 myo-
blasts, a cell line widely used as a model for Duchenne
muscular dystrophy (DMD) [27]. In C2C12 cells trans-
duced with Dmd sgRNAs, we detected an RT-PCR prod-
uct that corresponds to the normal splice product
containing exon 23. Sequencing these RT-PCR products
revealed that only Dmd-sg2 efficiently edited Dmd exon
23, as evidenced by mixed sequence peaks beyond the
sgRNA target site (Additional file 1: Figure S9). In cells
transduced with Dmd-sg2, we also detected an RT-PCR
product corresponding to exon 22 spliced to exon 24
(Fig. 4c, d). Thus targeting exon 23 with one sgRNA
might be sufficient to induce partial exon skipping and
produce an intact dystrophin open reading frame. DMD
is a classic example of a disease in which a small amount
of functional restoration can provide substantial clinical
benefit [28].
Discussion
Whereas gene inactivation is most often the goal of
CRISPR-mediated editing, our findings identify exon
skipping as an unintended consequence of genome edit-
ing. We also show that exon skipping can result from
indels that cause alternative splicing or from larger dele-
tions that remove exons. Novel splice isoforms could
encode proteins that retain partial function and should
be carefully considered when interpreting phenotypes
that result from CRISPR-induced mutations.
The frequency with which CRISPR-induced indels cause
exon skipping is difficult to predict. Nevertheless, exon
skipping caused by point mutations—including nonsense,
missense, and translationally silent mutations—is well
documented [29–32] and our results complement a recent
study, which showed that CRISPR-mediated editing of the
human FLOT1 gene can cause exon skipping by alterna-
tive splicing [18]. Roles for nonsense-mediated decay or
cis-acting regulatory elements have been proposed, but
mechanisms remain elusive. DNA damage has also been
Fig. 3 Cas9 nuclease activity required for skipping of one or more exons. a RT-PCR analysis of Ctnnb1 mRNA in KP cells transduced with lentiviruses
that encode sgCtnnb1.2 and nuclease-defective Cas9 (dCas9), dCas9-KRAB fusion, or WT Cas9. RT-PCR was performed using primers in exons 2 and 7
on transduced KP cell populations after puromycin selection and FACS sorting. The exon length and reading frame phase are shown. Only
the exon 2-4 splice product retains an in-frame β-Catenin coding sequence. b RT-PCR analysis of Ctnnb1 mRNA in KP cells transduced with lentiviruses
that encode Cas9 and sgGFP, sg3, or sg5. “–”, untreated
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shown to regulate exon skipping [33]. Our data do not
resolve whether the DNA damage, the indel, or the
premature stop codon induces exon skipping, but they are
consistent with the model that some indel mutations
disrupt cis-acting sequences that promote splicing [29].
Future studies are needed to determine how CRISPR-
induced indels cause alternative splicing and identify rules
for predicting when exon skipping will occur.
We detected an unexpectedly high frequency of large
deletions induced by CRISPR using a single sgRNA. We
and others previously showed that two sgRNAs can gen-
erate large genomic deletion or inversion [34, 35]. How-
ever, large deletions induced by a single sgRNA have not
been systematically analyzed in the literature. We ini-
tially missed these large deletions with the short-range
PCR assays typically used to genotype CRISPR clones.
We therefore recommend that, whenever possible, long-
range PCR be used to genotype CRISPR clones. In many
cases, large deletions will disrupt gene function and
accomplish the goal of a CRISPR-mediated genome
editing experiment. But our findings warrant careful
analysis of editing events, because the aberrant juxtapos-
ition and splicing of exons could result in neomorphic
alleles.
Although exon skipping is an unintended consequence
of CRISPR-mediated editing, we have shown that exon
skipping can produce mRNAs that encode gain-of-
function or partially functional proteins. Thus, exon
skipping induced by CRISPR-mediated editing might be
harnessed as a way to restore partial function to disease
genes, in much the way that exon skipping induced by
antisense oligonucleotides is being explored as a thera-
peutic to treat genetic diseases that result from splicing
mutations [36].
Methods
CRISPR vectors
sgRNAs (Additional file 1: Table S1) were cloned into
the lentiV2 (Addgene 52961) or pX330 (Addgene 42230)
vectors using standard protocols [37].
Fig. 4 An sgRNA targeting exon 23 of Dmd can partially restore in-frame dystrophin mRNA. a Schematic of sgRNA targeting and skipping of mouse
Dmd exon 23 and location of primers for RT-PCR analysis. Skipping of exon 23 will generate in-frame mRNA. b sgRNA target sites in Dmd
exon 23. c RT-PCR analysis of C2C12 mouse myoblast cells transduced with lentiviruses that encode Cas9 and sgDmd1, 2, 3, or 4. The expected band
sizes are 353 bp and 140 bp. M molecular marker. d Sequence analysis of the 140-bp cDNA band from sgDmd2-treated cells confirmed
splicing of exon 22 to exon 24
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Cell culture and infection
Cell culture conditions were as described [34]. A total of
293 fs cells were used to package lentiviruses encoding
individual sgRNA and Cas9. KP cells or C2C12 cells
were infected with lentiV2 lentiviruses and selected with
puromycin. For Fig. 3a, cells were transduced with
sgCtnnb1.2 cloned into lentiGuide-Puro vector (Addgene
52963), lenti Cas9-Blast (Addgene 52962), dCas9-BFP
(Addgene 46910), or dCas9-KRAB-BFP (Addgene 46911).
Cells were selected with puromycin, blasticidin, or FACS
sorted for BFP.
Isolation of single-cell clones
KP or NIH-3T3 cells were transduced with lentiviruses
Cas9 and sgRNAs targeting Kras, Ctnnb1, or p65 and
were selected with puromycin for four days. For each
transduction, 500 puromycin-resistant cells were seeded
into a 100-mm dish and cultured until cell colonies were
observed under a microscope. Individual colonies were
transferred to 12-well plates—one colony per well—and
grown to confluence. Genomic DNA and total RNA was
isolated and PCR or RT-PCR was used to identify clones
with indels, deletions, or insertions and exon skipping.
Genomic PCR products were cloned into a TOPO vector
to sequence alleles with indels or deletions.
CRISPR-induced insertion/deletion detection
Genomic DNA from cells was harvested by quick extrac-
tion buffer (Epibio), sgRNA target sites were amplified by
PCR, and the products were sequenced on an Illumina
NextSeq 500 [34]. We mapped the reads to the reference
sequence using BWA (version 0.7.5) and SAMtools
(version 0.1.19). VarScan2 (version 2.3) was used to
identify insertions and deletions with the “pileup2in-
del” mode and parameters “–min-var-freq,” “–min-
avg-qual,” and “–p-value.”
RNA-seq and bioinformatics analysis
RNA-seq libraries were generated using Illumina TruSeq
kit, as described [38]. Paired-end 75-nt sequencing was
performed using NextSeq. Reads were trimmed and
primer sequences were removed using Trimmomatic
(v 0.30). Reads were aligned to the mm10 genome
using STAR (version 2.3.0e) with default parameters
and uniquely mapping reads were selected. Redundant
read pairs were removed using Samtools (version 0.0.19).
For each gene annotated in GENCODE M7, the number
of reads per gene was calculated using HTSeq. Percent
exon 2 inclusion (Percentage Splicing Index, PSI or Ψ) for
Kras was calculated as: (exon 1-2 + exon 2-3)/(exon 1-2 +
exon 2-3 + exon 1-3). For global alternative splicing ana-
lysis, alternatively spliced exons were called using MISO
0.5.3 with default settings [39] and filtered with stringent
cutoffs (ΔΨ ≥ 0.2, total reads ≥ 10, and Bayes factor ≥ 10).
Western blot analysis
Protein lysates from cultured cells were prepared in
RIPA buffer with proteinase and phosphatase inhibitors.
Proteins were separated on 4–12% NuPage Bis-Tris gels
(Life Technologies, NP0321), transferred to nitrocellu-
lose membrane, and probed with 1:1000 anti-β-Catenin
antibody (BD 610154) or 1:5000 anti-Actin antibody
(CST 8457).
RT-PCR and TOPO cloning
RNA was purified using RNeasy Mini Kit (Qiagen). First
strand cDNA was synthesized using Superscript (ABI)
and target sequences were amplified using LA-Taq
(Clontech) or Herculase II (Agilent). Primers were listed
in Additional file 1: Table S2. Gel bands were quantified
using the ImageQuant TL software. Exon skipping prod-
ucts were gel purified, re-amplified using the same PCR
protocol to increase yield, and cloned into a TOPO
vector. TOPO clones were submitted to Genewiz for
sequencing. Representative results from two lentiviral
infections are shown.
Additional files
Additional file 1: Supplemental Figures and Tables 1–3. (PDF 4407 kb)
Additional file 2: Supplemental Table 4. (XLSX 32 kb)
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